

FINANCIAL RESULTS
for the first quarter of
2024

08/05/2024



KEY FIGURES

Summary

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Operating revenue(1)	151.2	201.6	(50.5)	-25%
Gross profit(2)	85.6	125.3	(39.7)	-32%
EBITDA(3)	25.9	66.5	(40.6)	-61%
EBIT(4)	19.3	60.7	(41.4)	-68%
Net profit(5)	15.0	47.5	(32.5)	-68%
Purchases of property, plant and equipment and intangible assets ("Capex")	9.0	4.9	4.1	83%
FCF(6)	6.6	19.7	(13.1)	-67%
Gross profit as % of operating revenue	56.6%	62.2%		-5.5 pp
EBITDA as % of operating revenue	17.1%	33.0%		-15.9 pp
EBIT as % of operating revenue	12.8%	30.1%		-17.4 pp
Net profit as % of operating revenue	9.9%	23.5%		-13.6 pp
Capex as % of operating revenue	5.9%	2.4%		3.5 pp
FCF as % of operating revenue	4.3%	9.8%		-5.4 pp

	As of March 31, 2024	As of Dec 31, 2023	Growth	% Growth
Net debt (€m)(7)	67.2	38.6	28.6	74%

Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding.

(1) Operating revenue refers to revenue.

(2) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.

(3) EBITDA calculated as profit before interest, taxes, depreciation and amortization.

(4) EBIT calculated as profit before taxes and interest.

(5) Net profit refers to profit for the period.

(6) Free Cash Flow (FCF) calculated as net cash generated from operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment plus interest received.

(7) Net debt composed of equity securities, plus deposits, plus financial derivatives, plus cash and cash equivalents, less current and non-current financial debt.

The consolidated financial statements of Grupo ROVI for the first quarter of 2024 and the comparative information for 2023 (balance sheet) and for the first quarter of 2023 (consolidated income statement and cash flow statement) are attached to this report (see Appendix 1). The figures for the first quarter of 2024 and the first quarter of 2023 are unaudited figures and the figures as of December 31, 2023 are audited figures.

CONTENTS

HIGHLIGHTS FIRST QUARTER 2024	3
GROUP MANAGEMENT REPORT	8
INCOME STATEMENT	8
REVENUES	8
SPECIALTY PHARMACEUTICAL BUSINESS	10
LOW MOLECULAR WEIGHT HEPARINS	11
OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS	12
CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS	13
CDMO BUSINESS	13
OTHER INCOME	13
COSTS	13
GROSS PROFIT	14
RESEARCH AND DEVELOPMENT EXPENSES	14
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	14
DEPRECIATION	14
NET FINANCE RESULT	15
EFFECTIVE TAX RATE	15
FINANCIAL PERFORMANCE	15
DIVIDEND	17
FINANCIAL POSITION	18
LIQUIDITY	21
OUTLOOK	24
R&D UPDATE	24
ESG	25
KEY OPERATING AND FINANCIAL EVENTS	26
APPENDIX 1	32
APPENDIX 2	36

HIGHLIGHTS FIRST QUARTER 2024


ROVI CLOSES THE QUARTER WITH OPERATING REVENUE OF 151.2 MILLION EUROS

- Operating revenue was 151.2 million euros in the first quarter of 2024, a 25% decrease on the first quarter of 2023, mainly due to the CDMO business. This division generated (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first quarter of 2023, when ROVI had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and, (ii) lower revenues related to the activities carried out to prepare the plant for the production of the vaccine under the agreement with Moderna.
- In April 2024, ROVI announced that its subsidiary ROVI Pharma Industrial Services, S.A.U. ("ROIS") entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company. Under the terms of the agreement, ROIS will provide a high-speed production line at the ROIS' San Sebastián de los Reyes facility in Madrid, with an estimated annual capacity of 100 million units. Commercial production is expected to commence in 2026, and as from 2027, which is expected to be the first full recurrent manufacturing year, ROVI's CDMO division expects to have a positive revenue increase impact ranging between 20% and 45% over 2023 sales.
- In March 2024, the U.S. Food and Drug Administration (FDA) approved the marketing of Risvan® (Risperidone ISM®) in the United States to treat schizophrenia in adults. Additionally, following normal practice, the FDA has required that, as a post-marketing commitment, a pharmacokinetic study be conducted to evaluate exposure to Risvan® approximately equivalent to the daily administration of 6 mg of oral risperidone. The clinical protocol for the study will be reviewed and agreed previously with the FDA and the final report on the clinical study will be submitted by July 2026. This additional study does not affect approval or commercialization.
- ROVI has likewise obtained approval for the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults in Canada and Australia.
- In March 2024, ROVI announced the creation, jointly with Insud Pharma S.L. and Invierte Economía Sostenible SICCC, SME, S.A. (the investment company of Centro para el Desarrollo Tecnológico Industrial EPE - CDTI) of Terafront Farmatech, a limited company (Sociedad de responsabilidad limitada) engaged in the research and development of advanced therapies. This alliance reinforces ROVI's commitment to innovation by expanding its R&D product pipeline beyond its ISM® technology.
- In January 2024, the FDA inspected the company's active substance manufacturing plant in Granada with a satisfactory result. The inspection focused on the processes of manufacture and control of the active substance to be used in the manufacture of Moderna's mRNA COVID-19 vaccine. This result


authorises Moderna to market the vaccine manufactured by ROVI in the United States.

- Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 5.4 million euros in the first quarter of 2024. Okedi® sales in the first quarter of 2024 were 2.4 times those of the first quarter of 2023.
- Sales of the heparin franchise (low molecular weight heparins (LMWH) and other heparins) decreased by 8% to 56.3 million euros in the first quarter of 2024, mostly due to the decrease in orders from partners in the first quarter of 2024, since they still hold a high level of stock from the last quarter of 2023.
- Good performance of Neparvis® and Orvatez®, of which sales increased by 8% and 2% respectively, in the first quarter of 2024 compared to the same period of 2023, rising to 12.2 million euros and 6.6 million euros respectively.
- Gross margin was 56.6% in the first three months of 2024, which represents a decrease of 5.5 percentage points mainly due to the decrease in sales generated from the manufacture of the COVID-19 vaccine in the first quarter of 2024 compared to the same period of 2023, when they added higher margins to the Group.
- Net profit was 15.0 million euros in the first quarter of 2024.

REVENUE BY REGION (%)



REVENUE BY BUSINESS UNIT (€Mn)



OUTLOOK

For 2024, ROVI expects its operating revenue to **decrease by a mid-single-digit percentage** in comparison with 2023. Notwithstanding, there are certain factors that have been considered when calculating this guidance that, although they could be relevant to the estimates, are difficult to specify at present, including, among others:

1. First, the saturation of the National Health Systems due to the low vaccination ratios during the 2023 COVID-19 campaign could favour a more successful vaccination campaign in 2024. However, as of today's date, the Company is not in a position to forecast how demand and production might evolve for the vaccination campaign in 2024.
2. Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at ROVI's facilities in Madrid and the current high demand for CDMO services in the market might favour obtaining new business, with the resulting sales impact. This would have to be taken into consideration but cannot be estimated at present.
3. Finally, subsequent to the granting of marketing authorisation for Risvan® by the United States FDA in March 2024, it is expected to start marketing the product on the United States market through a partner. The potential sales of this product in 2024 will depend on the terms of the agreement that ROVI establishes with its potential partner, which could also affect the estimates for 2024.

LAUNCHING OF A SHARE BUY-BACK PROGRAMME

ROVI informed that the Company launched, effective as of 26 July, 2023, a share buy-back programme (the "Buy-Back Programme"), in accordance with the following terms (see further information on page 29):

1. **Purpose and scope:** the Buy-back Programme's purpose is to redeem own shares of ROVI (share capital reduction) while, at the same time, boost the remuneration of the ROVI shareholder by increasing the profit per share.
2. **Term:** from 26 July 2023 for a period of 12 months.
3. **Maximum monetary amount:** up to 130,000,000 euros.
4. **Maximum number of shares to be acquired:** 2,700,000 shares of the Company, representing approximately 5% of the Company's share capital on 26 July 2023.

As of 30 April 2024, ROVI had executed approximately 95.59% of the buy-back programme, having acquired 2,166,075 shares for an amount of 124.3 million euros.



Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: "2024 is a year of transition that is critically important in establishing the bases for ROVI's future growth. In this context, we are very excited about the FDA's approval for the marketing of Risvan® in the United States. This event is a unique milestone in the Company's history, since it is the first of our own products to receive marketing authorisation in the United States, a market with great value-added, since it is the largest market in the world for long-acting injectable antipsychotics. Likewise, we continue to consolidate our international presence with Okedi® with the approval of the product in Canada and Australia. We believe in Okedi®'s potential and have increased sales in countries where the product had already been launched, multiplying sales by 2.4 times

to 5.4 million euros in the first quarter of 2024. Innovation is one of ROVI's hallmarks. We continue to progress with the phase I clinical trial of the three-monthly formulation of letrozole (Letrozol LEBE) and the phase I clinical trial in Europe of our three-monthly formulation of risperidone, reflecting a clear commitment to our ISM® technology, which we hope will be one of the Company's growth drivers in the future. Additionally, in March 2024, we announced the incorporation of a public-private investment vehicle to develop advanced, innovative and emerging medicines, therapies and/or technologies jointly with Insud Pharma S.L. and Invierte Economía Sostenible SICCC, SME, S.A. (investment company of Centro para el Desarrollo Tecnológico Industrial EPE – CDTI). This represents an opportunity to contribute to placing Spain in a leading position in the clinical research of new therapies, with the capacity to translate this research into manufacturing and thus improve the availability of new therapies to patients. Since the first COVID-19 vaccines were launched in December 2020, ROVI as a manufacturer of the Moderna vaccine, has been a fundamental pillar in providing a swift, flexible, and effective response to take the COVID-19 vaccine to all corners of the planet. We remain committed to the technological and qualitative standard of our CDMO business and continue to invest to increase our production capacities and be able to produce many more pharmaceutical units in the future. Additionally, in January 2024, we received FDA approval for the manufacture of the active substance of the COVID-19 vaccines at our Granada plant. This, together with the FDA approval received in September 2023 for our injectables manufacturing plants in Madrid, San Sebastián de los Reyes and Alcalá de Henares for the fill and finish of COVID-19 vaccine syringes, shows our commitment to the quality and safety of our service. Our low-molecular-weight heparin business decreased 8%, mainly due to the lower volume of orders from partners, who still hold high inventory levels from the fourth quarter of 2023. We remain committed to our heparin division and are investing to become self-sufficient

in obtaining crude and sodium heparin in order to be present in all the low-molecular-weight heparin manufacturing phases. We hope this investment will help increase future heparin division margins and that the crude heparin plant will come into operation in 2026. Additionally, heparin raw material prices are currently falling significantly. We expect this decrease to continue and to have a positive effect on the division's gross margin from 2025 onwards".

GROUP MANAGEMENT REPORT

for the quarterly period ending March 31st, 2024

INCOME STATEMENT

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Operating revenue(1)	151.2	201.6	(50.5)	-25%
Other income(2)	0.2	0.3	(0.1)	-33%
Total revenue(3)	151.3	201.9	(50.5)	-25%
Cost of goods sold(4)	(65.7)	(76.5)	10.8	-14%
Gross profit(5)	85.6	125.3	(39.7)	-32%
% margin(11)	56.6%	62.2%		-5.5 pp
R&D expenses(6)	(6.1)	(5.2)	(0.9)	17%
SG&A(7)	(53.6)	(53.6)	0.0	0%
Share of profit in associates and joint ventures	0.0	0.0	0.0	56%
EBITDA(8)	25.9	66.5	(40.6)	-61%
% margin(11)	17.1%	33.0%		-15.9 pp
EBIT(9)	19.3	60.7	(41.4)	-68%
% margin(11)	12.8%	30.1%		-17.4 pp
Finance Income/(Costs)	(0.3)	0.4	(0.7)	n.a.
Profit before income tax	19.0	61.2	(42.2)	-69%
Income tax	(4.0)	(13.7)	9.7	-70%
Effective tax	21.3%	22.4%		-1.1 pp
Net profit(10)	15.0	47.5	(32.5)	-68%
Net profit attributable to parent company	15.0	47.5	(32.5)	-68%
Profit attributable to minority interests	0.0	0.0	0.0	n.a.

(1) Operating revenue refers to revenue.

(2) Other income includes the recognition of government grants on non-financial non-current assets and other.

(3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other.

(4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use.

(5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.

(6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

(7) SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.

(8) EBITDA calculated as profit before interest, taxes, depreciation and amortization.

(9) EBIT calculated as profit before taxes and interest.

(10) Net profit refers to profit for the period.

(11) The gross margin and the EBITDA and EBIT margins are calculated as the result of dividing the gross profit, the EBITDA and the EBIT, respectively, by revenue, expressed as a percentage.

REVENUES

Total revenue by business unit

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Specialty pharmaceutical business	101.1	104.3	(3.3)	-3%
CDMO business	50.1	97.3	(47.2)	-48%
Operating revenue(1)	151.2	201.6	(50.5)	-25%
Other income(2)	0.2	0.3	(0.1)	-33%
Total revenue(3)	151.3	201.9	(50.5)	-25%

(1) Operating revenue refers to revenue excluding the recognition of government grants on non-financial non-current assets and other.

(2) Other income includes the recognition of government grants on non-financial non-current assets and other.

(3) Total revenue calculated as operating revenue plus the recognition of government grants on non-financial non-current assets and other.

Operating revenue decreased 25% to 151.2 million euros in the first quarter of 2024. This decrease was mainly caused by a drop in contribution of the CDMO business, sales of which fell to 50.1 million euros from 97.3 million euros in the first quarter of 2023, due to: (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first quarter of 2023, when ROVI had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and, (ii) lower revenues related to the activities to prepare the plant for the production of the vaccine under the agreement with Moderna. Additionally, sales from the specialty pharmaceutical business decreased 3% to 101.1 million euros, compared to 104.3 million euros in the first quarter of 2023. **Total revenue** fell 25% to 151.3 million euros in the first quarter of 2024.

Sales outside Spain decreased 37% in the first quarter of 2024, compared to the first quarter of 2023, to 80.7 million euros, mainly due to the decrease in sales from the manufacture of the COVID-19 vaccine. Sales outside Spain represented 53% of operating revenue in the first quarter of 2024 compared to 64% in the first quarter of 2023.

SPECIALTY PHARMACEUTICAL BUSINESS

Sales of the specialty pharmaceutical business

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Prescription-based pharmaceutical products	87.5	92.4	(4.8)	-5%
LMWH franchise	54.3	59.3	(4.9)	-8%
Enoxaparin biosimilar	34.6	34.9	(0.3)	-1%
Bemiparin (Hibor)	19.7	24.4	(4.7)	-19%
Sales in Spain	15.4	17.3	(1.9)	-11%
International sales	4.3	7.1	(2.8)	-39%
Okedi	5.4	2.2	3.2	145%
Neparvis	12.2	11.3	0.9	8%
Volutsa	2.4	5.0	(2.6)	-52%
Vytorin & Orvatez	6.6	6.6	0.0	0%
Other products	9.9	11.9	(2.0)	-17%
Discounts to the National Health System	(3.4)	(3.9)	0.5	-13%
Contrast agents and other hospital products	13.2	11.7	1.5	13%
Other products	0.3	0.3	0.0	11%
Total specialty pharmaceutical business	101.1	104.3	(3.3)	-3%

Sales of **prescription-based pharmaceutical** products decreased 5% to 87.5 million euros in the first quarter of 2024.

Sales of the **heparin franchise** (Low Molecular Weight Heparins and other heparins) decreased by 8% to 56.3 million euros in the first quarter of 2024. Heparin sales represented 37% of operating revenue in the first quarter of 2024 compared to 30% in the first quarter of 2023.

Heparin franchise

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
LMWH franchise	54.3	59.3	(4.9)	-8%
Enoxaparin biosimilar	34.6	34.9	(0.3)	-1%
Bemiparin (Hibor)	19.7	24.4	(4.7)	-19%
Sales in Spain	15.4	17.3	(1.9)	-11%
International sales	4.3	7.1	(2.8)	-39%
Other heparins ¹	2.0	2.2	(0.2)	-8%
Heparins franchise	56.3	61.4	(5.1)	-8%

LOW MOLECULAR WEIGHT HEPARINS

Sales of **Low Molecular Weight Heparins (LMWH)** (enoxaparin biosimilar and bemiparin) decreased by 8% to 54.3 million euros in the first quarter of 2024 mostly due to the decrease in orders from partners in the first quarter of 2024, since they still hold a high level of stock from the last quarter of 2023.

IN € MILLIONS	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024
Enoxaparin biosimilar	44.2	37.9	37.1	33.6	34.9	39.6	33.6	39.8	34.6
Bemiparin (Hibor)	30.0	25.8	20.0	27.9	24.4	20.2	22.8	26.9	19.7
Sales in Spain	17.5	17.2	15.7	16.5	17.3	14.6	14.2	15.6	15.4
International sales	12.5	8.6	4.4	11.5	7.1	5.6	8.6	11.4	4.3
Total LMWH sales	74.2	63.7	57.2	61.6	59.3	59.8	56.3	66.7	54.3

Sales of the **enoxaparin biosimilar** slightly decreased to 34.6 million euros in the first quarter of 2024.

ROVI commenced the marketing of its enoxaparin biosimilar in Germany in 2017; in UK, Italy, Spain, France, Austria, Latvia and Estonia in 2018; in Portugal, Poland, Costa Rica, Finland, and Sweden in 2019; in South Africa, Israel, Peru, Holland, Panama, and the Dominican Republic in 2020; in Canada, Belgium, Malaysia, Albania, North Macedonia, Guatemala, El Salvador, Honduras, Georgia, Bahamas, Jamaica, Gabon, Democratic Republic of Congo and Trinidad and Tobago in 2021; in Brazil, Luxembourg, Colombia, Bosnia and Herzegovina and Kosovo in 2022; and in Jordan and Sri Lanka in 2023.

¹ Other heparins are reported in the "Contrast agents and other hospital products" line. These figures include Normoparin sales which were not included in the Q1 2023 figure when it was released.

Bemiparin sales decreased 19% to 19.7 million euros in the first quarter of 2024. International sales of bemiparin decreased by 39% to 4.3 million euros. This decrease was mainly linked to (i) fewer orders from partners, (ii) declining sales in Turkey and Jordan; and (iii) the political-economic instability of some Middle East countries. Sales of bemiparin in Spain (Hibor®) showed a decrease of 11% to 15.4 million euros in the first quarter of 2024 compared to the first quarter of 2023, mainly due to lower penetration of the product in the prophylaxis segment. Nevertheless, ROVI expects full-year sales of bemiparin to increase by a low-single-digit percentage in 2024 compared to 2023.

OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS

Sales of **Neparvis®**, a specialty product from Novartis, launched in Spain in December 2016, indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction, increased 8% to 12.2 million euros in the first quarter of 2024, compared to 11.3 million euros in the first quarter of 2023.

Sales of **Volutsa®**, a specialty product from Astellas Pharma indicated for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia, launched in Spain in February 2015, decreased by 52% to 2.4 million euros in the first quarter of 2024 mainly due to a product price reduction of 47% in the second quarter of 2023.

Sales of **Vytorin® and Orvatez®**, specialty products from Organon & Co. ("Organon") indicated as adjunctive therapy to diet in patients with hypercholesterolemia, remained stable at 6.6 million euros in the first quarter of 2024. Orvatez® sales rose 2% to 6.6 million euros in the first quarter of 2024, compared to 6.5 million euros in the first quarter of 2023. ROVI ceased to distribute Vytorin® as of 31 January 2023.

Sales of **Okedi®**, the first ROVI product based on its leading-edge drug delivery technology, ISM®, and indicated for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, totaled 5.4 million euros in the first quarter of 2024. Okedi® sales multiplied the 2023 first-quarter sales by 2.4. In the first quarter of 2024, it was approved in the United States (under the brand name Risvan®), Canada and Australia; in 2023, it was launched in Portugal, Italy, Austria, Greece and Serbia; and in 2022, it was launched in Germany, UK and Spain.

- In Germany, the product continues to be received very positively in the medical education and dissemination activities carried out by ROVI. Currently, a new training project for nurses is under preparation in order to improve the administration of Okedi® in hospitals and continue to increase the products' sales.
- In the United Kingdom, the product is still in the introduction phase in the "trusts" (entities that manage the health areas).
- In Spain, the product is available in 100% of the autonomous communities and is marketed in over 90% of hospitals. Additionally, 100% of the psychiatrists contacted have taken part in ROVI training events and 45% of them have experience in using the drug. Likewise, the capture of market share in the retail and hospital markets is progressing favourably.

- In Portugal, sales of the product are developing very positively. In the first quarter of 2024, Okedi® was being marketed in 54% of the hospitals.
- In Italy, access to doctors continues to be very positive. In the first quarter of 2024, 96% of psychiatrists had received training in the product, 82% of them receiving three or more visits. Likewise, Okedi® is being marketed recurrently in 45% of the main hospitals. Sales are expected to grow and the product may be present in all the main hospitals by the end of 2024.
- In Austria, penetration of the product is being very positive. Okedi® was launched in the fourth quarter of 2023 and, in the first quarter of 2024, ROVI's salesforce had visited 50% of targeted psychiatrists.

ROVI ceased to promote and distribute **Xelevia®** (sitagliptin) and **Velmetia®** (sitagliptin and metformin), two antidiabetic drugs from Merck Sharp and Dohme ("MSD"), as of 31 January 2024. Sales of both products were 1.2 million euros in the first quarter of 2024 compared to 2.4 million euros in the first quarter of 2023.

CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS

Sales of **contrast imaging agents and other hospital products** increased by 13% to 13.2 million euros in the first quarter of 2024. This increase is due to a higher market penetration of radiological contrasts.

CDMO BUSINESS

CDMO sales fell by 48% to 50.1 million euros in the first quarter of 2024 in comparison to the first quarter of 2023, mainly due to (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to the first quarter of 2023, when ROVI had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and, (ii) lower revenues related to the activities carried out to prepare the plant for the production of the vaccine under the agreement with Moderna.

OTHER INCOME

Other income (subsidies) decreased by 0.1 million euros to 0.2 million euros in the first quarter of 2024 compared to the first quarter of 2023, mainly due to lower subsidies received in the period.

COSTS

GROSS PROFIT

Gross profit decreased 32% to 85.6 million euros in the first quarter of 2024 compared to the first quarter of 2023. Gross margin showed a decrease of 5.5 percentage points, from 62.2% in the first quarter of 2023 to 56.6% in the first quarter of 2024. This drop is mainly due to the lower revenues generated from the manufacture of the COVID-19 vaccine in the first quarter of 2024 compared to the same period of 2023, when they added higher margins to the Group.

In the first quarter of 2024, low-molecular-weight heparin (LMWH) raw material prices decreased by around 49% in comparison with the first quarter of 2023. ROVI expects this decline to accelerate throughout the year. Nevertheless, despite this price decrease, the impact on gross margin remained negative in the first quarter of 2024 due to the length of the LMWH manufacturing process, where the raw material currently being used has been stocked for several months and was purchased at higher prices. However, a positive impact on gross margin is expected to be seen from 2025.

RESEARCH AND DEVELOPMENT EXPENSES

R&D expenses increased 17% to 6.1 million euros in the first quarter of 2024. They were mainly related to (i) the development of the phase I of Letrozole LEBE and (ii) the development of the phase I of a new formulation of Risperidone ISM® for a 3-monthly injection. Both projects were in the preparation phase in the first quarter of 2023.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

SG&A expenses remained stable at 53.6 million euros in the first quarter of 2024 compared to the same period of the previous year due to an efficient cost containment policy. "Employee benefit expenses (excl. R&D)" increased 12% in the first quarter of 2024 versus the first quarter of 2023 mainly due to a 10.3% wage increase under the General Collective Agreement for the Chemical Industry. In addition, despite the Okedi® launch phase that is currently underway in Europe, ROVI was able to decrease "Other operating expenses (excl. R&D)" by 11% in the first quarter of 2024 in comparison to the first quarter of 2023.

SG&A expenses

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Employee benefit expenses (excl. R&D)	29.5	26.4	3.1	12%
Other operating expenses (excl. R&D)	24.1	27.2	(3.1)	-11%
Total SG&A expenses	53.6	53.6	0.0	0%

DEPRECIATION

Depreciation and amortisation expenses increased by 14% to 6.6 million euros in the first quarter of 2024, as a result of the new property, plant and equipment and intangible asset purchases made during the last year.

NET FINANCIAL COST


Net financial cost amounted to 0.3 million euros in the first quarter of 2024, compared to net financial income of 0.4 million euros in the first quarter of 2023. This decrease was mainly due to (i) higher expenses related to negative exchange differences and (ii) higher financial expenses.

EFFECTIVE TAX RATE

The **effective tax rate** was 21.3% in the first quarter of 2024 compared to 22.4% in the first quarter of 2023. This decrease in the effective tax rate was due to (i) a decrease in "Profit before income tax," and (ii) an increase in tax credits derived from research and development expenses compared to the first quarter of 2023.

FINANCIAL PERFORMANCE

Million euros



⁽¹⁾ Net profit refers to the profit for the period.

⁽²⁾ Gross profit calculated as total revenue less change in inventories of finished goods and work in progress and raw materials and consumables used.

⁽³⁾ SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets minus research & development expenses.

⁽⁴⁾ R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

EBITDA

EBITDA totaled 25.9 million euros in the first quarter of 2024, a decrease of 61% compared to the first quarter of 2023, reflecting a 15.9 percentage point decrease in the EBITDA margin, which was down to 17.1% in the first quarter of 2024 from 33.0% in the first quarter of 2023.

EBIT

EBIT decreased by 68% to 19.3 million euros in the first quarter of 2024, reflecting a 17.4 percentage point decline in the EBIT margin, which was down to 12.8% in the first quarter of 2024 from 30.1% in the first quarter of 2023.

NET PROFIT

Net profit decreased by 68%, from 47.5 million euros in the first quarter of 2023 to 15.0 million euros in the first quarter of 2024.

Non-controlling interests refer to ROVI's partners in Glicopepton Biotech, S. L.

PRE-R&D/FLAT R&D

EBITDA “Pre-R&D”, calculated excluding R&D expenses, decreased by 55%, from 71.7 million euros in the first quarter of 2023 to 32.0 million euros in the first quarter of 2024, reflecting a 14.4 percentage point decrease in the EBITDA margin to 21.2% in the first quarter of 2024 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in the first quarter of 2024 as in the first quarter of 2023, EBITDA would have decreased by 60% to 26.8 million euros, reflecting a 15.3 percentage point decrease in the EBITDA margin to 17.7% in the first quarter of 2024, down from 33.0% in the first quarter of 2023 (see “Flat R&D costs” columns of the table below).

EBIT “Pre-R&D”, calculated excluding R&D expenses, decreased by 61%, from 65.9 million euros in the first quarter of 2023 to 25.4 million euros in the first quarter of 2024, reflecting a 15.9 percentage point decrease in the EBIT margin to 16.8% in the first quarter of 2024 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in the first quarter of 2024 as in the first quarter of 2023, EBIT would have decreased by 67% to 20.2 million euros, reflecting a 16.8 percentage point decline in the EBIT margin to 13.4% in the first quarter of 2024, down from 30.1% in the first quarter of 2023 (see “Flat R&D costs” columns of the table below).

Net profit “Pre-R&D”, calculated excluding R&D expenses, decreased by 62%, from 51.5 million euros in the first quarter of 2023 to 19.7 million euros in the first quarter of 2024 (see “Pre-R&D costs” columns of the table below). Likewise, recognising the same amount of R&D expenses in the first quarter of 2024 as in the first quarter of 2023, net profit would have decreased by 67% to 15.7 million euros (see “Flat R&D costs” columns of the table below) in the first quarter of 2024.

Pre-R&D/Flat R&D

IN € MILLIONS	Reported		Pre-R&D costs			Flat R&D costs		
	Q1 2024	Q1 2023	Q1 2024	Q1 2023	% Growth	Q1 2024	Q1 2023	% Growth
Operating revenue(1)	151.2	201.6	151.2	201.6	-25%	151.2	201.6	-25%
Other income(2)	0.2	0.3	0.2	0.3	-33%	0.2	0.3	-33%
Total revenue(3)	151.3	201.9	151.3	201.9	-25%	151.3	201.9	-25%
Cost of sales(4)	(65.7)	(76.5)	(65.7)	(76.5)	-14%	(65.7)	(76.5)	-14%
Gross profit(5)	85.6	125.3	85.6	125.3	-32%	85.6	125.3	-32%
% margin(11)	56.6%	62.2%	56.6%	62.2%	-5.5 pp	56.6%	62.2%	-5.5 pp
R&D expenses(6)	(6.1)	(5.2)	0.0	0.0	n.a.	(5.2)	(5.2)	n.a.
SG&A(7)	(53.6)	(53.6)	(53.6)	(53.6)	0%	(53.6)	(53.6)	0%
Share of profit in associates and joint ventures	0.0	0.0	0.0	0.0	n.a.	0.0	0.0	n.a.
EBITDA(8)	25.9	66.5	32.0	71.7	-55%	26.8	66.5	-60%
% margin(11)	17.1%	33.0%	21.2%	35.6%	-14.4 pp	17.7%	33.0%	-15.3 pp
EBIT(9)	19.3	60.7	25.4	65.9	-61%	20.2	60.7	-67%
% margin(11)	12.8%	30.1%	16.8%	32.7%	-15.9 pp	13.4%	30.1%	-16.8 pp
Net profit(10)	15.0	47.5	19.7	51.5	-62%	15.7	47.5	-67%
% margin(11)	9.9%	23.5%	13.1%	25.5%	-12.5 pp	10.4%	23.5%	-13.2 pp

(1) Operating revenue refers to revenue.

(2) Other income includes the recognition of government grants on non-financial non-current assets and other.

(3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other.

(4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use.

(5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.

(6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

(7) SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets minus research & development expenses.

(8) EBITDA calculated as profit before interest, taxes, depreciation and amortization.

(9) EBIT calculated as profit before taxes and interest.

(10) Net profit refers to profit for the period.

(11) The gross margin and the EBITDA, EBIT and net profit margins are calculated as the result of dividing the gross profit, the EBITDA, the EBIT and the net profit, respectively, by revenue, expressed as a percentage.

DIVIDEND

ROVI's Board of Directors will put a proposal to the Ordinary General Meeting for distribution of a dividend of 59,617,632.48 euros, equivalent to 1.1037 per share entitled to receive it. This represents approximately 35% of the 2023 consolidated net profit attributed to the parent company, broken down as follows:

- Application of profit: the entire profit of Laboratorios Farmacéuticos ROVI, S.A. for 2023, 12,071,013.68 euros, was applied to the dividend distribution; and
- Additionally, a further 47,546,618.80 euros was distributed as dividends charged to the freely-available reserves accounted for as "Retained earnings".

FINANCIAL POSITION

Balance Sheet

IN € MILLIONS	March 31, 2024	Dec 31, 2023	Growth	% Growth
Assets				
Non-current assets	293.2	290.6	2.7	1%
Current assets	485.4	509.3	(23.9)	-5%
Total assets	778.7	799.9	(21.2)	-3%
Equity	523.8	543.5	(19.7)	-4%
Liabilities				
Non-current liabilities	63.6	56.5	7.1	13%
Financial debt	59.6	52.2	7.4	14%
Current liabilities	191.2	199.8	(8.6)	-4%
Financial debt	22.1	13.2	9.0	68%
Total liabilities	254.9	256.4	(1.5)	-1%
Total equity and liabilities	778.7	799.9	(21.2)	-3%

TOTAL ASSETS

ROVI's **total assets** decreased by 3%, from 799.9 million euros as of December 31, 2023 to 778.7 million euros as of March 31, 2024, mainly because of (i) a decrease of 12.2 million euros in "Cash and cash equivalents", mostly due to the decrease in "Profit before income tax" and the purchase of treasury shares as part of ROVI's buy-back programme; and (ii) a decrease of 11.8 million euros in "Trade and other receivables", mainly related to the billing linked to CDMO clients.

EQUITY

ROVI's **equity** decreased by 19.7 million euros to 523.8 million euros as of March 31, 2024. This decrease resulted from the share buy-back programme executed in the first quarter of 2024.

TOTAL LIABILITIES

ROVI's **total liabilities** decreased by 1% from 256.4 million euros as of December 31, 2023 to 254.9 million euros as of March 31, 2024, mainly due to a decrease of 35.3 million euros in the "Trade and other payables" caption. This is partially offset by (i) an increase of 13.4 million euros in the "Contract liabilities" item, which mainly related to amounts billed to customers that have not yet been taken to profit and loss as service revenue as of March 31, 2024; and (ii) an increase of 16.3 million euros in the "Financial debt" item.

As of March 31, 2024, ROVI **total debt** increased to 81.8 million euros. Debt with public administration, which is 0% interest rate debt, represented 11% of total debt as of March 31, 2024.

Total Debt

IN € THOUSANDS	March 31, 2024	Dec 31, 2023	Interest rate
Bank borrowings	55,221	37,745	0.68-4.78
Debt with public administration	9,095	8,890	0
Financial liabilities for leases	17,458	18,792	-
Total	81,774	65,427	

As of March 31, 2024, bank borrowings increased by 17.5 million euros. In December 2017, ROVI announced the European Investment Bank (EIB) had granted it a loan to support its investments in Research, Development and Innovation. The loan was for 45 million euros. As of March 31, 2024, ROVI had drawn 45 million euros against this credit line; 5 million euros at a variable interest rate of Euribor at 3 months + 0.844% (the latest interest rate paid was 4.78% in April 2024) and 40 million euros at a fixed interest of 0.681%. Repayment of the variable interest loan started in October 2021 (quarterly repayments) and its current outstanding balance is 3.2 million euros. Likewise, repayment of the fixed interest loan started in February 2023 (quarterly repayments) and its current outstanding balance is 32.9 million euros. The credit at a variable interest matures in 2028 and the credit at a fixed interest matures in 2029, both includes a grace period of 3 years.

In July 2022, ROVI announced that the European Investment Bank (EIB) had granted it a new loan to support its investments in Research, Development and Innovation. The loan is for 50 million euros with a repayment period of 10 years, has a three-year grace period, and may be drawn down over a term of two years. As of March 31, 2024, ROVI had drawn 10 million euros against this new credit at a variable rate of Euribor at 3 months + 0.655% (the interest rate for the first repayment is 4.625%).

Additionally, ROVI signed two credit policies: one in September 2023 for 20 million euros and another in March 2024 for 20 million euros, both with conditions of Euribor 3 months + 0.50%. As of March 31, 2024, ROVI had drawn 9 million euros against the policy signed in September 2023.

GROSS CASH POSITION AND NET DEBT


As of March 31, 2024, ROVI had a **gross cash position** of 14.5 million euros, compared to 26.8 million euros as of December 31, 2023, and **net debt** of 67.2 million euros, compared to net debt of 38.6 million euros as of December 31, 2023.

Gross cash position and net debt

IN € MILLIONS	March 31, 2024	Dec 31, 2023
Equity securities	–	0.0
Deposits	1.4	1.4
Cash and cash equivalents	13.1	25.3
Derivatives (net)	0.0	–
Gross cash position	14.5	26.8
Financial debt	(81.8)	(65.4)
(Net debt)/Net cash	(67.2)	(38.6)

Net cash generated in operating activities amounted to 15.5 million euros in the first quarter of 2024, compared to 24.5 million euros in the same period of 2023. Net cash generated from operating activities excluding changes in working capital decreased 28% to 29.2 million euros in the first quarter of 2024 from 40.8 million euros in the same period of 2023.

Million euros



(1) Net cash/Net debt is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt.

LIQUIDITY

Cash Flow

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Cash flow from operating activities	15.5	24.5	(9.0)	-37%
Cash flow from investing activities	(9.2)	(4.8)	(4.3)	89%
Cash flow from financing activities	(18.6)	(3.2)	(15.5)	n.a
Net increase/ (decrease) in cash	(12.2)	16.5	(28.8)	n.a
Cash at the beginning of the period	25.3	124.9	(99.6)	-80%
Cash at the end of the period	13.1	141.5	(128.4)	-91%

CASH FLOW FROM OPERATING ACTIVITIES

Cash flow from operating activities decreased to 15.5 million euros in the first quarter of 2024 from 24.5 million euros in the same period of 2023. This decrease was mainly due to:

- the decrease of 42.2 million euros in "Profit before income tax";
- the decrease of 35.3 million euros in the "Trade and other payables" item in the first quarter of 2024, compared to a decrease of 29.8 million euros in the first quarter of 2023; and
- the increase of 19.1 million euros in the "Trade and other receivables" item in the first quarter of 2024, compared to an increase of 25.5 million euros in the first quarter of 2023.

These negative impacts were partially offset by:

- the increase of 2.7 million euros in the "Inventory" item in the first quarter of 2024 compared to a decrease of 12.3 million euros in the first quarter of 2023; and
- the booking of 6.1 million euros under the "Cash flow from contract manufacturing services" caption in the first quarter of 2024 relating to payments received but not yet allocated to the income statement, compared to the (22.5) million euros recognized in the first quarter of 2023.

CASH FLOW FROM INVESTING ACTIVITIES

ROVI invested 9.0 million euros in the first quarter 2024, compared to 4.9 million euros in the first quarter of 2023.

Purchases of property, plant and equipment and intangible assets ("Capex")

IN € MILLIONS	Q1 2024	Q1 2023	Growth	% Growth
Madrid Injectable plant	0.1	0.0	0.0	66%
San Sebastián de los Reyes plant	0.2	0.1	0.1	n.a
Granada plant	0.0	0.0	0.0	n.a
Alcalá de Henares plant	0.3	0.3	(0.0)	-10%
Escúzar plant ⁽¹⁾	0.1	1.1	(1.0)	-90%
Expenditure on maintenance and other capex	0.3	0.3	0.0	12%
Maintenance Capex	1.0	1.8	(0.8)	-43%
ISM industrialisation	0.5	0.6	(0.2)	-25%
Glicopepton	1.2	0.1	1.1	n.a
New filling lines and operations expansion	6.3	2.4	3.9	n.a
Investment Capex	8.0	3.1	4.9	155%
Total Capex	9.0	4.9	4.1	83%

(1) In the first quarter 2023 press release, this figure was reported as Investment Capex.

FREE CASH FLOW

Free cash flow decreased to 6.6 million euros in the first quarter of 2024 from 19.7 million euros in the first quarter of 2023.

Free cash flow

IN € MILLIONS	Q1 2024	Q1 2023
Net cash generated from (used in) operating activities	15.5	24.5
Purchases of intangible assets	(0.1)	(0.0)
Purchases of property, plant and equipment	(8.9)	(4.9)
Proceeds from sale of property, plant and equipment	0.0	0.0
Interest received	0.0	0.1
Free cash flow	6.6	19.7

CASH FLOW FROM FINANCING ACTIVITIES

Cash flow from financing activities was (18.6) million euros in the first quarter of 2024 versus (3.2) million euros in the first quarter of 2023. This decrease was mainly attributable to (i) ROVI's share buy-back programme executed in the first quarter of 2024; and (ii) zero income obtained from the sale of treasury shares in the first quarter of 2024 versus 29.5 million euros in the first quarter of 2023.



Javier López-Belmote Encina, Deputy Chairman and Chief Financial Officer of ROVI, said: *"after successfully overcoming 2023, the first post-pandemic year, and demonstrating the resilience of our business, 2024 will be a year of transition in which value is created for the future. In this context, total revenue was 151.3 million euros, 25% lower than the same period of last year because of lower revenue from the production of the COVID-19 vaccine. Apart from that, our business showed stability in terms of revenue and gross margin in the first quarter of 2024. In addition, we were able to reduce our operating expenses (excluding R&D expenses and employee benefit expenses) by 11% as the result of an efficient cost containment policy. Likewise, even though the gross margin decreased by 5.5 percentage points due to a lower contribution from the CDMO business, we*

expect the COVID-19 vaccine production in the second half of the year and the lower revenue from the technology transfer activities to have a positive impact on the Group's gross margin. Moreover, we expect a further improvement in this margin from 2025 onwards as a result of the drop in low-molecular-weight heparin raw material prices. Likewise, we are very satisfied with the execution of the share buy-back programme, which we hope to complete before the summer. ROVI's commitment to innovation is reflected in the figures for the first three months of 2024. We are in a new growth phase and we hope that the strength of our balance sheet will allow us to take further opportunities to expand our sales and obtain a higher return on our assets".

OUTLOOK

For 2024, ROVI expects its operating revenue to **decrease by a mid-single-digit percentage** in comparison with 2023. Notwithstanding, there are certain factors that have been considered when calculating this guidance that, although they could be relevant to the estimates, are difficult to specify at present, including, among others:

1. First, the saturation of the National Health Systems due to the low vaccination ratios during the 2023 COVID-19 campaign could favour a more successful vaccination campaign in 2024. However, as of today's date, the Company is not in a position to forecast how demand and production might evolve for the vaccination campaign in 2024.
2. Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at ROVI's facilities in Madrid and the current high demand for CDMO services in the market might favour obtaining new business, with the resulting sales impact. This would have to be taken into consideration but cannot be estimated at present.
3. Finally, subsequent to the granting of marketing authorisation for Risvan® by the United States FDA in March 2024, it is expected to start marketing the product on the United States market through a partner. The potential sales of this product in 2024 will depend on the terms of the agreement that ROVI establishes with its potential partner, which could also affect the estimates for 2024.

R&D UPDATE

ISM® technology platform

Okedi® (Risperidone ISM®) is the first ROVI product based in its leading-edge drug delivery technology, ISM®. It is a novel investigational antipsychotic for the treatment of schizophrenia with once-monthly (every 28 days) injections which has been developed and patented by Laboratorios Farmacéuticos ROVI S.A. and which, as of the first injection, provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

On 15 February 2022, the European Commission authorised the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, and it was launched in 2022 in Germany, UK and Spain and in 2023 in Portugal, Italy, Austria, Greece and Serbia.

On 21 March 2024, ROVI received authorisation from Health Canada for the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults throughout Canada. ROVI has likewise obtained approval in Australia.

On 29 March 2024, ROVI reported that the United States Food and Drug Administration (FDA) had authorised the marketing of Risvan® (Risperidone ISM®) for the treatment of schizophrenia in adults. Additionally, following normal practice, the FDA has required that, as a post-marketing commitment, a pharmacokinetic study be conducted to

evaluate exposure to Risvan® approximately equivalent to the daily administration of 6 mg of oral risperidone. The clinical protocol for the study will be reviewed and agreed previously with the FDA and the final report on the clinical study will be submitted by July 2026. This additional study does not affect approval or commercialization.

Likewise, ROVI's R&D team is progressing in the development of a new formulation of Risperidone for a 3-monthly injection, which would complement the current 4-weekly formulation of Risperidone ISM® for the maintenance treatment of adult patients with clinically stable schizophrenia. The company is currently conducting a phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of various candidate formulations at different dose strengths and injection sites; patient's recruitment for this study began in September of 2023.

Lastly, the company decided to commence the clinical development of a new three-monthly formulation of Letrozole (hereinafter, Letrozole LEBE), rather than the initially planned annual formulation of Letrozole ISM®. The objective of this new development is to reach bioequivalence in the plasma levels of letrozole in comparison with the daily administration of oral doses of Femara® 2.5 mg.

With this new clinical programme for Letrozole LEBE, ROVI estimates it could reduce the research times in comparison to those for an annual formulation of the product, thus making it likely that the three-monthly formulation could be marketed several years earlier and, furthermore, the investment necessary to attain the objectives of this project could also be reduced.

Accordingly, ROVI is currently carrying out a phase I clinical trial in Europe to evaluate the pharmacokinetics, safety and tolerability of single ascending doses of Letrozole LEBE, at different strengths, in voluntary healthy post-menopausal women (LEILA-1 study). This first clinical trial of Letrozole LEBE began in July 2023.

ESG

For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world rating of environmental, social and corporate governance (ESG) risks drawn up by Sustainalytics, a leading independent ESG research, rating and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI has revalidated its first place among 431 companies rated in the pharmaceutical industry group and remains in 22nd place among a total of 895 companies rated in the entire sector, which includes "biotechnology companies, pharmaceutical laboratories and laboratory equipment companies."

In the rating process carried out in July 2023, Sustainalytics has analysed the company's performance in sustainability aspects considered material in the pharmaceutical sector, highlighting ROVI's sound management of ESG risks related to product quality and safety, corporate governance, business ethics, human capital, the fight against climate change and anti-corruption and anti-bribery practices. ROVI has obtained a higher than-average score in areas such as the board's involvement in the Company's environmental

and social aspects, implementation of the environmental policy and a sound quality and safety programme for products and services, as well as the integration of ethical practices into all tiers of the organisation.

Commitment to sustainability

In 2022, ROVI approved its ESG Master Plan 2023-2025, a document that sets out 19 strategic ESG goals. With a three-year horizon, the Group has established a roadmap for attaining the Sustainable Development Goals (SDGs) of the United Nations Agenda 2030, with which ROVI, as a member of the Global Compact, is aligned.

The Group focuses its action on five priority areas:

- Becoming a leader in governance committed to sustainability.
- Commitment to sustainable management to combat the global environmental challenges: fight against climate change, promotion of the circular economy and efficient water management.
- Positioning itself as a key player in caring for persons and integrating specialised and diverse talent.
- Promoting responsible management of the supply chain, ensuring ethical and environmental standards in each one of its links.
- Promoting R&D&I activities by establishing partnerships with key players.

In addition, ROVI, as a member of the United Nations Global Compact, upholds, by adopting and disseminating it, the inclusion of the principles of this Compact, as well as other international instruments, especially in the spheres of human rights, workplace practices, the environment and the fight against corruption.

KEY OPERATING AND FINANCIAL EVENTS

ROVI announces agreement to manufacture pre-filled syringes

Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), informed (by publication of the inside information number 2207 dated 25th April 2024) that its subsidiary, ROVI’s wholly owned CDMO platform, ROVI Pharma Industrial Services, S.A.U. (hereinafter “ROIS”) had entered into an agreement to support the manufacture of pre-filled syringes for a global pharmaceutical company.

Under the terms of the agreement, ROIS will provide a high-speed production line at the ROIS’ San Sebastián de los Reyes facility in Madrid, with an estimated annual capacity of 100 million units. The agreement includes the technology transfer for aseptic filling and has a commercial production term of five years subject to the terms of the agreement, beginning on the date of manufacture of the first commercial lot. After the technology

transfer and regulatory approval, commercial production is expected to commence in 2026. As from 2027, which is expected to be the first full recurrent manufacturing year, the ROVI's Group CDMO division expects to have a positive revenues increase impact ranging between 20% and 45% over 2023 sales.

ROIS is well-equipped to support the production of pre-filled syringes given its deep expertise in the current good manufacturing practice (cGMP) production of sterile injectable products across both vials and pre-filled syringes.

Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: *"We are delighted to be able to support in the manufacture of medicine that is able to prolong the life of millions of people. Our proven experience in the manufacture of high-valued-added injectables and the expansion of our production capacities have positioned us to help meet the rapidly growing demand, which requires a high degree of technological capability."*

ROVI receives the FDA's approval of Risvan® as a treatment for schizophrenia

ROVI informed (by publication of the relevant information number 27772 dated 2nd April 2024) that the U.S. Food and Drug Administration (FDA) had authorised the marketing of Risvan® (Risperidone ISM®) for the treatment of schizophrenia in adults.

Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults, which, as of the first injection, provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.

This approval is based on the positive results of the pivotal PRISMA-3 study on the efficacy and safety of Risperidone ISM® in schizophrenia patients⁽²⁾. The results obtained in this study show that the two different doses (75 mg and 100 mg once a month) have achieved the prespecified primary and secondary efficacy endpoints for treatment of patients with moderate to severe symptoms of schizophrenia. The primary efficacy endpoint, the PANSS⁽³⁾ total score (mean difference, CI: 95%), improved significantly with Risperidone ISM® 75 mg and 100 mg from the beginning until day 85, with adjusted differences of -13.0 (17.3 to -8.8; p <0.0001) and -13.3 (-17.6 to -8.9; p<0.0001), respectively, in comparison with the placebo. Significantly improved mean changes for the secondary endpoint, the CGI-S⁽⁴⁾ score, were also obtained for Risperidone ISM® in comparison with the placebo, -0.7 (-1.0 to -0.5; p<0.0001), for both doses, from the beginning until day 85. The significant statistical improvement for both efficacy results was observed as early as 8 days after the first injection. The most frequently reported treatment-emergent adverse events were increased blood prolactin (7.8%), headaches

2 Correll, C.U., Litman, R.E., Filts, Y. et al. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. *npj Schizophr* 6, 37 (2020). <https://doi.org/10.1038/s41537-020-00127-y>

3 Positive and Negative Syndrome Scale: the Positive and Negative Syndrome Scale is a medical scale based on a semi-structured interview that rates the severity of the symptoms of schizophrenia patients in three domains: positive symptoms, negative symptoms and general psychopathology symptoms.

4 Clinical Global Impression-Severity scale: la escala de Impresión Clínica Global-Gravedad rates the severity of schizophrenia through a question put to the doctor: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?".

(7.3%), hyperprolactinemia (5%) and weight increase (4.8%). No important new or unexpected safety information was reported. Likewise, patients who successfully completed the double-blind period were offered the opportunity to continue in a long-term, open-label 12-month extension phase with once every four weeks injections of Risperidone ISM® (75 mg or 100 mg). New, clinically stable patients ("de novo" patients) were also able to enter this open phase of the study. Long-term treatment was observed to be effective, safe and well tolerated in adult patients with schizophrenia, regardless the initial severity of the disease or whether they had been treated previously with Risperidone ISM® during an acute exacerbation or switched from stable doses of oral risperidone⁽⁵⁾. Likewise, Risperidone ISM® provided a swift and sustained improvement in functioning (both social and personal) and health-related quality of life. These findings, together with a quick onset of effectiveness, could help strengthen the therapeutic alliance and possibly lead to an earlier hospital discharge. Furthermore, the patient's functioning either continued to improve or remained stable with long-term treatment⁽⁶⁾.

"We are very excited about the FDA's approval of Risvan® because we think our medicine will be able to contribute to the clinical management of schizophrenia patients, helping to improve treatment adherence", commented Juan López-Belmonte Encina, ROVI's Chairman and Chief Executive Officer.

ROVI, Insud Pharma and Invierte (CDTI) create a company for the research and development of advanced therapies

ROVI informed (by publication of the relevant information number 27397 dated 12th March 2024) of the agreement that has been concluded with Insud Pharma S.L. and Invierte Economía Sostenible SICCC, SME, S.A. (investment company of Centro para el Desarrollo Tecnológico Industrial EPE – CDTI) to incorporate, together with these two entities, a limited company (Sociedad de responsabilidad limitada) engaged in the research and development of advanced therapies.

This agreement, which was approved at the meeting of the Council of Ministers held on 12 March 2024, falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE), promoted by the Spanish Government. This PERTE concerns the creation of a public-private investment vehicle to develop advanced, innovative and/or emerging medicines, therapies and/or technologies. The goal is to favour the deployment of the technical and industrial capacities necessary to generate a high performance healthcare system intended to protect health by providing an immediate and flexible response to healthcare challenges and favouring sustainability.

The share capital of this new entity will be 49% held by the Ministry of Science, Innovation and Universities through the company Invierte, while Insud Pharma and ROVI will hold 25.5% each. The shareholders undertake to make an initial combined contribution of 74,867,346.94 euros. The investment will be made in accordance with

5 Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. *Schizophr Res.* 2021 Nov 27;239:83-91.

6 Litman R, Naber D, Anta L, Martínez J, Filts Y, Correll CU. Personal and Social Functioning and Health-Related Quality of Life in patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. *Neuropsychiatr Dis Treat.* 2023 Jan 25;19:219-232.

the needs of the projects defined in the future and will be subject to the shareholders' approval of the relevant business plan. Such investment could reach 220 million euros, which would be contributed by the public and private investors that are participating.

It is planned that Invierte's contributions could be made with European "Next Generation EU" funds, which include the EU Recovery and Resilience Facility established in Regulation (EU) 2921/241 of the European Parliament and of the Council of 12 February 2021.

Juan López-Belmonte, Chairman and CEO of ROVI, highlights the fact that this agreement *"represents an opportunity to help place Spain in a leading position in the clinical research of new therapies, with the capacity to translate this research into manufacturing and thus improve the availability of new therapies to patients. At ROVI, we are delighted to place our knowledge and experience at the service of this great public-private alliance that reinforces our commitment to innovation"*.

ROVI Share Buy-Back Programme

ROVI informed (by publication of the inside information number 1926 dated 26th of July 2023) that the Company launched, effective as of 26 July, 2023, a share buy-back programme (the "Buy-Back Programme"), in accordance with the following terms:

1. **Purpose and scope:** the Buyback Program's purpose is to redeem own shares of ROVI (share capital reduction) and, at the same time, boost the remuneration of the ROVI shareholder by increasing the profit per share.
2. **Term:** from 26 July 2023, and for a period of 12 months.
3. **Maximum monetary amount:** up to 130,000,000 euros, provided that the maximum price per share may not exceed that provided for by article 3.2 of Delegated Regulation 2016/1052.

The authorization granted by the general shareholders' meeting of the Company on 17 June 2021 established (a) a minimum price for the acquisition corresponding to the nominal value of the acquired shares and (b) a maximum price for the acquisition corresponding to a price not above the highest between (i) the last transaction carried out on the market by independent parties and (ii) the highest price of a purchase order amongst those contained in the orders book.

4. **Maximum number of shares to be acquired:** 2,700,000 shares of the Company, representing approximately 5% of the Company's share capital on 26 July 2023.
5. **Trading volume to be considered as reference:** the trading volume to be taken as a reference for the purposes of the provisions of article 3.3 of Delegated Regulation 2016/1052 for the entire duration of the buy-back program shall be 25% of the average daily volume of ROVI's shares on the trading venue on which the purchase is carried out during the twenty trading days prior to the date of the purchase.

As of 30 April 2024, ROVI had executed approximately 95.59% of the buy-back programme, having acquired 2,166,075 shares for an amount of 124.3 million euros.

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already present in more than 60 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its Enoxaparin biosimilar, developed in-house, in Europe and it is already marketed in 40 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.

For further enquiries, please contact:

Juan López-Belmonte Encina
Chairman and Chief Executive Officer
www.rovi.es

Javier López-Belmonte Encina
Deputy Chairman and Chief Financial Officer
www.rovi.es

Marta Campos Martínez
Head of Finance
+34 912444422
mcampos@rovi.es
www.rovi.es

Beatriz de Zavala Mazarredo
Investor Relations Analyst
+34 610 737 703
bdezavala@rovi.es
www.rovi.es

Victoria López-Belmonte
Investor Relations Analyst
+34 680 669 485
vlopez-belmonte@rovi.es
www.rovi.es

Forward-looking statements

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date after the date of this press release.

APPENDIX 1

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023

IN € THOUSANDS	March 31, 2024*	Dec 31, 2023
ASSETS		
Non-current assets		
Property Plant and Equipment	256,616	253,652
Intangible assets	33,294	33,902
Investments in joint ventures and associates	836	567
Deferred tax assets	2,437	2,343
Equity securities	–	24
Financial receivables	65	65
	293,248	290,553
Current assets		
Inventories	337,971	337,968
Trade and other receivables	131,488	143,314
Current income tax assets	32	–
Prepaid expenses	2,828	2,727
Derivative financial instruments	11	–
Cash and cash equivalents	13,085	25,322
	485,415	509,331
Total assets	778,663	799,884

* Unaudited figures

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023

IN € THOUSANDS	March 31, 2024*	Dec 31, 2023
EQUITY		
Equity attributed to the parent company	519,677	539,387
Share capital	3,241	3,241
Share premium	87,636	87,636
Legal reserve	673	673
Treasury shares	(142,331)	(107,676)
Retained earnings and voluntary reserves	555,531	385,199
Profit for the period	14,961	170,335
Accumulated other comprehensive income	(34)	(21)
Non-controlling interests	4,105	4,107
Total equity	523,782	543,494
LIABILITIES		
Non-current liabilities		
Financial debt	59,628	52,242
Deferred tax liabilities	1,139	1,515
Contract liabilities	1,618	1,431
Deferred income	1,250	1,359
	63,635	56,547
Current liabilities		
Financial debt	22,146	13,185
Trade and other payables	106,639	141,895
Current tax liabilities	9,722	5,255
Contract liabilities	52,280	39,044
Deferred income	459	464
	191,246	199,843
Total liabilities	254,881	256,390
Total equity and liabilities	778,663	799,884

* Unaudited figures

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS FOR MARCH 31, 2024 AND MARCH 31, 2023

IN € THOUSANDS	Q1 2024	Q1 2023
Revenue	151,175	201,630
Changes in inventories of finished goods and work in progress	30,528	14,173
Raw materials and consumables used	(96,244)	(90,713)
Employee benefit expenses	(32,305)	(29,201)
Other operating expenses	(27,629)	(30,539)
Work carried out by the Group on non-current assets	211	931
Amortisation and depreciation	(6,626)	(5,816)
Recognition of government grants on non-financial non-current assets and other	172	255
Share of profit in joint ventures and associates	14	9
OPERATING PROFIT (EBIT)	19,296	60,729
Finance income	3	70
Finance costs	(316)	(147)
Impairment and gain or loss on measurement of financial instruments	68	215
Exchange difference	(43)	300
FINANCE INCOME/(COSTS) - NET	(288)	438
PROFIT BEFORE INCOME TAX	19,008	61,167
Income tax	(4,049)	(13,710)
PROFIT FOR THE PERIOD	14,959	47,457
Profit for the period attributable to parent company	14,961	47,459
Profit attributable to minority interests	2	2

Unaudited figures

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR MARCH 31, 2024 AND MARCH 31,
2023

IN € THOUSANDS	Q1 2024	Q1 2023
Cash flows from operating activities		
Profit before tax	19,008	61,167
Adjustments for non-monetary transactions:		
Amortisation and depreciation	6,626	5,816
Finance income	(3)	(70)
Valuation allowance	(2,814)	(3,008)
Adjustments for changes in value of derivatives	(11)	129
Gain or loss on derecognition of financial assets and liabilities	(57)	(344)
Finance expenses	316	147
Exchange differences	43	(300)
Grants, distribution licenses and other deferred income	(258)	(328)
Share of profit in associates and joint ventures	(14)	(9)
Changes in working capital:		
Trade and other receivables	19,099	25,522
Inventories	2,700	(12,256)
Other current assets (prepaid expenses)	(101)	277
Trade and other payables	(35,306)	(29,806)
Other collections and payments:		
Cash flow from contract manufacturing services	6,147	(22,450)
Proceeds from distribution licenses	253	160
Income tax cash flow	(84)	(139)
Net cash generated from (used in) operating activities	15,544	24,508
Cash flows from investing activities		
Purchases of intangible assets	(135)	(16)
Purchases of property, plant and equipment (usage rights not included)	(8,856)	(4,896)
Proceeds from sale of property, plant and equipment	9	10
Proceeds from sale of financial investments	80	–
Investments in associates and joint ventures	(255)	–
Interest received	3	70
Net cash generated from (used in) investing activities	(9,154)	(4,832)
Cash flows from financing activities		
Repayments of financial debt	(3,470)	(3,594)
Proceeds from financial debt	19,600	562
Interest paid	(99)	(90)
Purchase of treasury shares	(34,658)	(29,734)
Reissue of treasury shares	–	29,525
Capital contribution to subsidiaries	–	172
Net cash generated from (used in) financing activities	(18,627)	(3,159)
Net (decrease) increase in cash and cash equivalents	(12,237)	16,517
Cash & cash equivalents at the beginning of the period	25,322	124,945
Cash and cash equivalents at the end of the period	13,085	141,462

Unaudited figures

APPENDIX 2

ALTERNATIVE PERFORMANCE MEASURES

In addition to the financial information prepared in accordance with International Financial Reporting Standards (“IFRSs”) taken from our financial statements, this document includes certain alternative performance measures (“APMs”) as defined in the ESMA (European Securities and Markets Authority) Guidelines on Alternative Performance Measures of 5 October, 2015 (ESMA/2015/1415), as well as some non-IFRS financial indicators. The financial measures contained in this document that are considered APMs or non-IFRS financial indicators have been prepared on the basis of the ROVI Group’s financial information but are not defined or set out in detail within the framework of the applicable financial information and have not been audited or reviewed by ROVI's auditors.

These APMs are considered figures that have been adjusted in respect of those that are presented in accordance with the International Financial Reporting Standards endorsed by the European Union (IFRS-EU), which form the applicable accounting framework for the consolidated financial statements of the ROVI Group. Therefore, the reader should consider them to complement the latter but not to replace them.

We use these APMs and non-IFRS financial indicators to plan, oversee and assess our performance. We consider the APMs and non-IFRS financial indicators to be useful to allow the management team and investors to compare the past or future financial performance, the financial situation and the cash flows. Notwithstanding, these APMs and non-IFRS financial indicators are considered complementary and are not intended to replace IFRS measures. Furthermore, other companies, including some in ROVI's sector, may calculate such measures differently, which reduces their usefulness for comparative purposes.

This document contains information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including their definitions and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs. The document is available on ROVI's website and may be accessed on the following link: (<https://www.rovi.es/en/shareholders-investors/financial-business-information>).

In this respect, in accordance with the Guidelines issued by the European Securities and Markets Authority (ESMA), in force since 3 July, 2016, in relation to the transparency of Alternative Performance Measures, ROVI provides below information concerning the APMs it considers significant that are included in this press release:

- **Operating revenue**

This APM shows the revenue that the group generates from its main business activities.

Operating revenue refers to revenue.

- **Other revenue**

Other revenue shows the grants obtained by the Group to develop its R&D&I and other projects.

Other revenue refers to the recognition of government grants on non-financial non-current assets and other.

- **Total revenue**

This APM shows all the group's revenues.

We calculate total revenue as revenue plus the recognition of government grants on non-financial non-current assets and other.

- **Cost of sales**

The cost of sales reflects the cost involved in producing or acquiring the products or services that ROVI sells.

The cost of sales is calculated as the amount of raw materials and consumables used plus that corresponding to the changes in inventories of finished goods and work in progress.

- **Gross profit**

Gross profit is an indicator that measures the direct profit that ROVI obtains from carrying out its income-generating activities.

We calculate gross profit as total revenue less cost of sales.

- **Gross margin or gross profit as % of operating revenue**

This APM is a percentage indicator that measures the direct profit that ROVI obtains from its operating revenue.

We calculate gross margin or gross profit as % of operating revenue as the percentage that the gross profit represents in the revenue (operating revenue).

- **Research & Development ("R&D") Expenses**

R&D expenses reflect expenses related to scientific research and technological development carried out by the company.

R&D expenses are calculated as the sum of employee benefits expenses and other operating expenses related to scientific research and technological development.

- **SG&A Expenses**

Selling, General & Administrative (SG&A) Expenses is an indicator that measures expenses related to the general internal operations and management of the company.

SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.

- **EBITDA**

EBITDA (Earnings Before Interest, Tax, Depreciation and Amortization) is an indicator that measures the group's operating profit before interest, taxes, impairment, depreciation and amortization have been deducted. Management uses it to assess the results over time, allowing a comparison with other companies in the sector.

We calculate EBITDA as profit before: taxes, interest, depreciation and amortization.

- **EBITDA margin or EBITDA as % of operating revenue**

This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest, taxes, impairment, depreciation and amortization are deducted.

We calculate EBITDA margin or EBITDA as % of operating revenue as the percentage that the EBITDA represents in the revenue (operating revenue).

- **EBITDA "Pre-R&D"**

This APM is used by ROVI to show EBITDA from the on-going business.

We calculate EBITDA "Pre-R&D" as EBITDA excluding: R&D expenses and non-recurring income and expenses.

- **EBIT**

EBIT (Earnings Before Interest and Taxes) is an indicator that measures the group's operating profit before interest and tax are deducted. Like EBITDA, Management uses it to assess the results over time, allowing a comparison with other companies in the sector.

We calculate EBIT as profit before: taxes and interest.

- **EBIT margin or EBIT as % of operating revenue**

This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest and tax are deducted.

We calculate EBIT margin or EBIT as % of operating revenue as the percentage that the EBIT represents in the revenue (operating revenue).

- **EBIT "Pre-R&D"**

This APM is used by ROVI to show EBIT from the on-going business.

We calculate EBIT "Pre-R&D" as operating profit for the period excluding: Research and Development expenses ("R&D") and non-recurring income and expenses.

- **Net profit**

Net profit is an indicator that measures the group's profit for the period.

We calculate Net profit as EBIT plus finance costs-net and income tax.

- **Net profit as % of operating revenue**

This APM is a percentage indicator that measures the profit for the period that ROVI obtains from its operating revenue.

We calculate net profit as % of operating revenue as the percentage that the net profit represents in the revenue (operating revenue).

- **Net profit “Pre-R&D”**

This APM is used by ROVI to show the profit for the period related to the on-going business.

We calculate net profit “Pre-R&D” as EBIT “Pre-R&D” plus:

- Finance costs-net; and
- Income tax. Net profit “Pre-R&D” income tax is calculated by applying the same effective tax rate as reported in the income statement of the period.

- **Gross cash position**

Gross cash position is an indicator that measures the amount of cash the group has at a specific point in time.

We calculate gross cash position as equity securities plus deposits plus financial derivatives plus financial assets at amortised cost plus cash and cash equivalents.

- **Net cash**

Net cash, also measured as financial debt or net debt, is the main indicator used by Management to measure the group’s indebtedness.

It is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt.

- **Capex**

Capex is an indicator used to better understand the investments made by the group in its operations.

We calculate Capex as purchases of property, plant and equipment and intangible assets.

- **Capex as % of operating revenue**

This APM is a percentage indicator that measures the group's investments in property, plant and equipment, and intangible assets to its operating revenues.

We calculate Capex as % of operating revenue as the percentage that the purchases of property, plant and equipment and intangible assets represents in the revenue (operating revenue).

- **Free Cash Flow (FCF)**

Free cash flow is an indicator that measures cash flow generation from operating and investment activities and is useful for evaluating the funds available for paying shareholder dividends and servicing debt.

We calculate free cash flow as net cash generated from or used in operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment and intangible assets plus interest received.

- **FCF as % of operating revenue**

This APM is a percentage indicator that measures the group's cash flow generation from operating and investment activities relative to its operating revenues.

We calculate FCF as % of operating revenue as the percentage that the free cash flow represents in the revenue (operating revenue).